Communicable Diseases, Imported

– First-in-class approach to targeting mitochondrial DNA polymerase (POLG) with disease modifying potential across mitochondrial DNA depletion syndromes (MDDS) and broader neurodegenerative diseases – – Regulating cellular bioenergetics to impede disease progression and severity across high unmet need indications – – Awarded grant from Parkinson’s UK to evaluate POLG activation mechanisms in Parkinson’s disease models – WALTHAM, MA, USA I April 03, 2025 I Pretzel Therapeutics, a leader in harnessing cellular energetics to develop novel treatments for a range of conditions spanning neurological, muscular atrophies, metabolic and rare disease, today announced that it has initiated recruitment in a Phase 1 clinical study of PX578, the lead therapeutic in its bioenergetics restoration franchise. The randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PX578 in healthy adult participants, with a potential clinical trial in MDDS patients planned for 2026. The initiation of our Phase 1 clinical trial of PX578 reflects the important progress we are making in turning our unique bioenergetics approach into a reality, with a deep, first-in-class pipeline. Share “The initiation of our Phase 1 clinical trial of PX578 reflects the important progress we are making in turning our unique bioenergetics approach into a reality, with a deep, first-in-class pipeline of energetics restoring and energetics modulating compounds to positively impact high unmet need indications,” said Jay Parrish, Ph.D., Chairman of the Board and Chief Executive Officer of Pretzel. “Our energetics restoration franchise, led by PX578, our small molecule POLG activator, has broad potential spanning from rare mitochondrial DNA depletion syndromes for which there are no disease-modifying treatments to larger neurodegenerative conditions, such as Parkinson’s and Alzheimer’s disease. We look forward to reporting further progress in the months to come.” The company also announced that it has been awarded grant funding from Parkinson’s UK to support evaluation of Pretzel’s POLG activation mechanism in Parkinson’s disease models in collaboration with Dr. Roberta Filograna’s lab at the Karolinska Institute, Stockholm, Sweden. “We’re excited to be funding Pretzel Therapeutics to take early but important steps in the development of a compound that has potential for the treatment of Parkinson’s. Targeting the mitochondria, specifically boosting levels of mitochondrial DNA, could lead to us finding a way to slow or stop Parkinson’s, something that no treatment can currently do,” said Professor David Dexter of Parkinson’s UK. About Pretzel Therapeutics Pretzel Therapeutics is dedicated to developing life-changing medicines with a broad pipeline of first-in-class treatments addressing novel targets within the mitochondria. By harnessing cellular energetics to modulate disease processes and improve survival, function and quality of life, we are ushering in a new treatment paradigm for a breadth of conditions spanning neurological, muscular atrophies, metabolic and rare disease. PX578, the lead therapeutic in Pretzel’s bioenergetics restoration franchise, represents a first-in-class approach to targeting mitochondrial DNA polymerase (POLG) across mitochondrial DNA depletion syndromes (MDDS). PX578 is in Phase 1 clinical development . POLRMT, the lead program in our energetics modulation franchise, targets mitochondrial RNA polymerase for the treatment of metabolic conditions including obesity. POLRMT is in late preclinical development. The company is headquartered in Waltham, MA and has research facilities in Mölndal, Sweden. For more information, visit www.pretzeltx.com . SOURCE: Pretzel Therapeutics

READING, England--( BUSINESS WIRE )--Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM ® Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus. 1 The vaccination schedule consists of two vaccine doses injected by the intramuscular route 6 months to 36 months apart but can be given up to 7 years apart. 1 This launch was based on data from 20 clinical studies in 14 countries across Europe, the Middle East, Asia and the Americas, involving more than 6,200 children aged 12 months to 15 years who have received at least one dose of the vaccine in the context of a clinical trial. 2 The data show that AVAXIM Junior is effective in inducing a protective antibody response within two weeks in over 95% of individuals, and in nearly 100% before the booster dose administered six months after the first dose. 3 Rebecca Catterick, UK and Ireland Sanofi Vaccines General Manager , said: “Hepatitis A is one of the most prevalent travel-related vaccine-preventable diseases, so the availability of effective options like AVAXIM Junior will offer parents peace of mind knowing that they can help protect their children when travelling to high-risk areas.” Hepatitis A is one of the most common vaccine-preventable, viral infections worldwide Hepatitis A, caused by the hepatitis A virus, is primarily transmitted through contaminated food and water or by direct contact with an infectious person. 4 Incidence of the disease is closely related to socio-economic conditions, so it is most prevalent in developing countries with poor sanitary conditions and hygiene practices. 4,5 It is the most common form of viral hepatitis 6 and the third most common vaccine-preventable infection among travelers. 7 ENDS About AVAXIM ® 80U Paediatric AVAXIM Junior is indicated for active immunisation against infection caused by the hepatitis A virus in children aged 12 months to 15 years inclusive. It can be used for both primary and booster vaccination and should be given according to official recommendations. 1 Most commonly observed side effects include pain at the injection site, a general feeling of discomfort or being unwell (malaise), headache and abnormal crying. 1,3 Most reactions were limited to the first few days following vaccination with spontaneous recovery. 1,3 AVAXIM Junior is a ready-to-use suspension for injection containing 80 antigen units of inactivated hepatitis A virus and is available in 0.5ml unidoses of suspension in pre-filled syringes with attached needles. 1 About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY References 1 AVAXIM Junior SmPC. May 2021 2 Sanofi Pasteur. Data on file. March 2017 3 Sanofi Pasteur. Avaxim®80U Pediatric. Clinical Core Data Sheet. 195- Pediatric Hepatitis A vaccine - CCDS – version 15 –24 September 2020 4 WHO. WHO position paper on Hepatitis A vaccines – June 2012. Wkly Epidemiol Rec, 2012;87(28/29):261-76. 5 WHO. Health Emergency and Disaster Risk Management Fact Sheets. WATER, SANITATION AND Hygiene. December 2017. Available at: https://cdn.who.int/media/docs/default-source/disaster-mngmt/risk-management-wash-december2017.pdf?sfvrsn=81ddcc1a_1&download=true [Accessed January 2023]. 6 Luxemburger C, Dutta AK. Overlapping epidemiologies of hepatitis A and typhoid fever: the needs of the traveler. J Travel Med. 2005 Apr;12 Suppl 1:S12-21. 7 Steffen R, Behrens RH, Hill DR, Greenaway C, Leder K. Vaccine-preventable travel health risks: what is the evidence—what are the gaps? J Travel Med. 2015;22(1):1-12. Job Code: MAT-XU-2300110 (V1.0) Date of Preparation: April 2023

BRUSSELS, Jan 4 (Reuters) - European Union government officials recommended on Wednesday that passengers flying from China to the EU should have a negative COVID-19 test before they board, as Beijing plans to ease travel restrictions despite a wave of new COVID infections. The recommendation comes from the EU's Integrated Political Crisis Response group (IPCR), which is a body made up of officials from the EU's 27 governments, and is in line with a recommendation made earlier by the European Commission. China plans to ease travel restrictions on Jan 8, despite a wave of new infections which has left Chinese hospitals and funeral houses overwhelmed . The IPCR also recommended that all passengers on flights to and from China should wear face masks, that EU governments introduce random testing of passengers arriving from China and that they test and sequence wastewater in airports with international flights and planes arriving from China. The IPCR said that, together with the European Centre for Disease Control, the Commission's foreign affairs department and the World Health Organisation would continue to monitor the epidemiological situation in the EU and developments in China. "The Member States agree to assess the situation and review the introduced measures by mid-January 2023," the IPCR said in statement. The European Centre for Disease Control (ECDC) said last week it did not currently recommend measures on travellers from China, because the variants circulating in China were already in the European Union. The ECDC also said EU citizens had relatively high vaccination levels and the potential for imported infections was low compared to daily infections in the EU, with healthcare systems currently coping. Our Standards: The Thomson Reuters Trust Principles.